Systemic inflammation and proinflammatory interleukin-17 signalling persist at the end of therapy in patients with metabolic syndrome and psoriasis, reducing the length of remission

Secukinumab in psoriasis: randomized, controlled phase 3 trial results assessing the potential to improve treatment response in partial responders (STATURE)

(2015) D. Thaçi et al.   BRITISH JOURNAL OF DERMATOLOGY

Efficacy and safety of brodalumab in subpopulations of patients with difficult-to-treat moderate-to-severe plaque psoriasis

(2015) Kim Papp et al.   JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY

A high level of clinical response is associated with improved patient-reported outcomes in psoriasis: analyses from a phase 2 study in patients treated with ixekizumab

(2015) E. Edson-Heredia et al.   JOURNAL OF THE EUROPEAN ACADEMY OF DERMATOLOGY AND VENEREOLOGY

Inflammatory markers of cardiovascular disease risk in Portuguese psoriatic patients: relation with narrow-band ultraviolet B and psoralen plus ultraviolet A

(2013) Susana Coimbra et al.   INTERNATIONAL JOURNAL OF DERMATOLOGY

Principal Determinants of the Length of Remission of Psoriasis Vulgaris After Topical, NB-UVB, and PUVA Therapy

(2012) Susana Coimbra et al.   AMERICAN JOURNAL OF CLINICAL DERMATOLOGY

Interleukin (IL)-22, IL-17, IL-23, IL-8, vascular endothelial growth factor and tumour necrosis factor-α levels in patients with psoriasis before, during and after psoralen-ultraviolet A and narrowband ultraviolet B therapy

(2010) S. Coimbra et al.   BRITISH JOURNAL OF DERMATOLOGY

Circulating adipokine levels in Portuguese patients with psoriasis vulgaris according to body mass index, severity and therapy

(2010) S Coimbra et al.   JOURNAL OF THE EUROPEAN ACADEMY OF DERMATOLOGY AND VENEREOLOGY

C-reactive protein and leucocyte activation in psoriasis vulgaris according to severity and therapy

(2009) S Coimbra et al.   JOURNAL OF THE EUROPEAN ACADEMY OF DERMATOLOGY AND VENEREOLOGY

Role of adiponectin and PBEF/visfatin as regulators of inflammation: involvement in obesity-associated diseases

(2008) Herbert Tilg et al.   CLINICAL SCIENCE

Impact of Body Mass Index and Obesity on Clinical Response to Systemic Treatment for Psoriasis

(2008) Luigi Naldi et al.   DERMATOLOGY

Serum Levels of IL-17 and IL-22 Are Reduced by Etanercept, but not by Acitretin, in Patients with Psoriasis: a Randomized-Controlled Trial

(2008) M. Caproni et al.   JOURNAL OF CLINICAL IMMUNOLOGY